Price Crosses Moving Average
|Bid||61.19 x 900|
|Ask||60.55 x 800|
|Day's Range||57.78 - 75.14|
|52 Week Range||56.06 - 120.03|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 26, 2023 - Jul 31, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||97.71|
Subscribe to Yahoo Finance Plus to view Fair Value for NVCRLearn more
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
ROOT, Switzerland, June 06, 2023--Novocure today is presenting positive results from the phase 3 LUNAR clinical trial in non-small cell lung cancer at the 2023 ASCO Annual Meeting.
ROOT, Switzerland, June 01, 2023--Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer®, the ASCO Foundation, to advance cancer research and education.
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
With a price-to-sales (or "P/S") ratio of 13.6x NovoCure Limited ( NASDAQ:NVCR ) may be sending very bearish signals at...
Should you buy Novocure stock right now? When a stock falls as much as Novocure has over the last couple of years or so, there's always an underlying reason. The main factor behind Novocure's decline is that its business isn't performing all that well.
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR)Q1 2023 Earnings CallMay 04, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and thank you for standing by.
NovoCure (NVCR) delivered earnings and revenue surprises of -38.89% and 4.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ROOT, Switzerland, May 04, 2023--Novocure Reports First Quarter 2023 Financial Results
In discussing healthcare tech stocks, it pays to understand what healthcare technology is broadly. Healthcare technology, also known as HealthTech, refers to any technology developed to improve the healthcare system. It encompasses everything from robotic-assisted surgery to telemedicine and Software. Notably, these technologies have been shown to reduce costs across the healthcare system. Indeed, most of us knows this needs to happen. Today’s healthcare industry is valued at $2 trillion, but is
ROOT, Switzerland, April 26, 2023--Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6.
ROOT, Switzerland, April 14, 2023--Novocure (NASDAQ: NVCR) today announced 27 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida.
The last three months have been tough on NovoCure Limited ( NASDAQ:NVCR ) shareholders, who have seen the share price...
ROOT, Switzerland, April 03, 2023--Novocure announced today that it will report financial results for the first quarter 2023 on May 4, 2023, before the U.S. financial markets open.
In this article, we will take a look at the 12 most promising healthcare stocks according to analysts. To see more such companies, go directly to 5 Most Promising Healthcare Stocks According to Analysts. 2023 is turning out to be a horrific year for financial markets as investors are starting to see a glimpse of […]
ROOT, Switzerland, March 29, 2023--Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors.
Key Insights Given the large stake in the stock by institutions, NovoCure's stock price might be vulnerable to their...
ROOT, Switzerland, March 16, 2023--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
Keeping with this theme, Federal Reserve Chair Jerome Powell said Tuesday that the bank is considering raising interest rates faster and farther than previously anticipated in order to tamp down inflation. Defensive stocks could be a good way to protect your portfolio from downside risk. Which defensive stocks are top buys right now?
ROOT, Switzerland, March 01, 2023--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering Optune on the List of Reimbursable Products and Services (LPPR) provided for in Article L165-1 of the Social Security Code was published in the Official Journal on February 28, 2023 and will become effective March 15, 2023.
ROOT, Switzerland, March 01, 2023--Novocure announced that the final patient has enrolled in the pivotal METIS study.
NovoCure ( NASDAQ:NVCR ) Full Year 2022 Results Key Financial Results Revenue: US$537.8m (flat on FY 2021). Net loss...
Shares of the novel oncology company NovoCure (NASDAQ: NVCR) are trading lower today following the company's 2022 fourth-quarter and full-year results release this morning. Although the company's financial results were essentially in line with Wall Street's consensus estimates for the three-month period, investors were clearly looking for a stronger quarter from the cancer company. Perhaps the most concerning issue is that NovoCure's net revenue fell by 4% in Q4 to $128.4 million, relative to the same period a year ago.
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR)Q4 2022 Earnings CallFeb 23, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Ingrid Goldberg Good morning, everyone, and thank you for joining us to review NovoCure's fourth-quarter and full-year 2022 performance.
NovoCure (NVCR) delivered earnings and revenue surprises of -12.50% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?